Botanix Pharmaceuticals (BOT) has had its application to use the novel sofpironium bromide gel to treat primary axillary hyperhidrosis rejected by the US Food and Drug Administration (FDA).
Source: https://themarketherald.com.au/botanix-pharmaceuticals-asxbot-suffers-setback-in-fda-approval-for-sofpironium-bromide-gel-to-treat-hyperhidrosis-2023-09-26/
Botanix Pharmaceuticals (BOT) has had its application to use the...
-
- There are more pages in this discussion • 2,769 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.010(2.67%) |
Mkt cap ! $574.9M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.5¢ | 35.5¢ | $6.090M | 16.50M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 101678 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 79000 | 2 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |